Stem Cell Manufacturing Market, By Type (Product, Services), By Application (Stem Cell Therapy, Drug Discovery and Development, Stem Cell Banking), By End-User (Pharmaceutical and Biotechnology Companies & CRO, Cell Banks and Tissue Banks, Academic & Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2024

Code : CMI5381

Pages :168

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Stem Cell Manufacturing Market Regional Insights

To learn more about this report, request sample copy

North America has established itself as the dominant region in the global stem cell manufacturing market with share of 40.2% in 2024. The U.S. alone accounts for over 50% of the total market share, attributed to heavy investments in R&D by both government and private players. Countries in the region have highly evolved healthcare systems compared to others globally, which has facilitated increased adoption of advanced therapeutics, including those derived from stem cells. The presence of top research universities and major biopharma companies has created a robust stem cell manufacturing ecosystem in North America. for instance, in April 2022, the Stem Cell Network (SCN) of Canada unveiled IGNITE 2022-2025, a three-year strategic blueprint funded by the Government of Canada through a USD 45 million allocation in Budget 2021. This initiative, IGNITE 2022-2025, is structured around three fundamental pillars: research, training, and knowledge dissemination. Each of these pillars plays a crucial role in positioning Canadian scientists and expertise at the forefront of global regenerative medicine (RM) endeavors.

Asia Pacific has emerged as the fastest growing regional market in recent times, primarily due to focus of countries like China, Japan, South Korea and India towards building healthcare infrastructure and stem cell research capabilities. China especially has aggressively pushed policies to drive innovative stem cell therapies development. This coupled with preference of large biopharma’s to establish facilities in Asia due to relatively lower costs and availability of skilled workforce, have positioned the region as an important player.